2026/27 National Genomic Test Directory updated in England in July 2026

On July 16, 2026, NHS England updated the 2026/27 National Genomic Test Directory (NGTD), initially published in April 2026. The directory lists genomic tests commissioned by NHS England and provided through Genomic Laboratory Hubs. 

The following parts of the directory were revised:

• National genomic test directory for haematological oncology (HaemOnc) (version 1.1)
• Haematological oncology (HaemOnc) eligibility criteria (version 1.1)
• National genomic test directory for cancer non-central nervous system (non-CNS) (version 16)

One new test was added to the directory for haematological oncology in the test package for myeloproliferative neoplasm.

Three new multi-target NGS panels were added to the directory for non-CNS cancers. All new tests are indicated for solid tumors in adults, specifically for carcinoma of unknown primary origin. One of the new tests comprises ctDNA (liquid biopsy): 

• M226.7 Multi-target ctDNA NGS panel - small variant (AKT1, APC, ALK, BRCA1, BRCA2, BRAF, CDKN2A, CTNNB1, EGFR, ESR1, HRAS, IDH1, FGFR2, FGFR3, KIT, KRAS, MLH1, NF1, NRAS, PDGFRA, PIK3CA, PTEN, RB1, RET, TSC1, TP53, TERT (promoter), VHL), copy number variant (BRCA1, BRCA2, PTEN), structural variant (ALK, BRAF, EML4, FGFR2, FGFR3, NTRK1, NTRK2, NTRK3, ROS1, MET (including exon 14 skipping), RET).

This news is just one of about 300 market access news and updates collected by our team in the premium subscription service MTRC Access Intelligence every week from more than 80 organizations. Access our paid service to stay on top of all developments, specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, six-week, no-obligation trial.